Hydrolysis of pyridoxal isonicotinoyl hydrazone and its analogs
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
An orally available iron chelator is desirable for the treatment of secondary iron overload. Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs effectively mobilize iron in vivo and in vitro, and are therefore promising candidates for this purpose. PIH analogs undergo significant amino acid-catalyzed hydrolysis in cell culture medium and in serum, achieving equilibrium with their corresponding aldehydes and hydrazides with half-times of 1-8 h. The extent of hydrolysis in RPMI is significant, even in experiments of a few hours' duration, although the half-life of PIH in phosphate-buffered saline (PBS) is approximately 24 h. Therefore, the biological effects (e.g., 59Fe mobilization, toxicity) of these iron chelators have been underestimated in previous studies. Measurement of the affinity of PIH analogs for Fe(3+) under conditions in which hydrolysis is minimal resulted in conditional affinity constants of 10(26) to 10(27) M, which are much lower than predicted by the overall formation constants determined under conditions that likely allowed extensive hydrolysis. These data indicate the importance of hydrolysis of PIH analogs in the interpretation of previous studies, and the importance of designing clinically useful analogs whose efficacies are not limited by hydrolysis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, pyridoxal isonicotinyl hydrazone (PIH) [1672,1715-1720] is a promising molecule (also proposed in anti-cancer therapy), although it is hydrolysed both in vivo and in vitro [1721].”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1721]
Citations
Cites
Critical Stability Constants: First Supplement
Martell, A. E., & Smith, R. M. (1982) · Springer eBooks · doi:10.1007/978-1-4615-6761-5 · Cited by 6,008
Practical management of iron overload
Porter, J. B. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03195.x · Cited by 378
Richardson, D., Tran, E., & Ponka, P. (1995) · Blood · doi:10.1182/blood.v86.11.4295.bloodjournal86114295 · Cited by 345
Self-citationEquilibria between Pyridoxal and Amino Acids and their Imines1
Metzler, D. E. (1957) · Journal of the American Chemical Society · doi:10.1021/ja01559a068 · Cited by 225
(1979) · FEBS Letters · doi:10.1016/0014-5793(79)80111-8 · Cited by 190
Kontoghiorghes, G. J., Aldouri, M. A., Hoffbrand, A. V., Barr, J., Wonke, B., Kourouclaris, T., & Sheppard, L. (1987) · BMJ · doi:10.1136/bmj.295.6612.1509 · Cited by 187
Poňka, P., Borová, J., Neuwirt, J., Fuchs, O., & Nečas, E. (1979) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(79)90100-4 · Cited by 183
Iron Chelators for Thalassaemia
Hershko, C., Konijn, A. M., & Link, G. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00726.x · Cited by 160
Baker, E., Richardson, D., Gross, S., & Ponka, P. (1992) · Hepatology · doi:10.1002/hep.1840150323 · Cited by 130
Self-citationToxicity of oral iron chelator L1
Berdoukas, V. A., Bentley, P., Frost, H., & Schnebli, H. (1993) · The Lancet · doi:10.1016/0140-6736(93)92443-w · Cited by 90
Research works printed but not linked: 1
- Martell, 1977, vol. 3
Cited by
Oximes and Hydrazones in Bioconjugation: Mechanism and Catalysis
Kölmel, D. K., & Kool, E. T. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00090 · Cited by 699
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Charkoudian, L. K., Dentchev, T., Lukinova, N., Wolkow, N., Dunaief, J. L., & Franz, K. J. (2008) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2008.08.001 · Cited by 49
Investigation of the stability of aromatic hydrazones in plasma and related biological material
Kovaříková, P., Mrkvičková, Z., & Klimeš, J. (2008) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2008.01.011 · Cited by 44
Metadata
- Authors
- Buss, J. L., & Ponka, P.
- Affiliations
- Jewish General Hospital (CA)
- Corresponding author
- Ponka, Prem
- ORCID
- Ponka, Prem
- Venue
- Biochimica et Biophysica Acta (BBA) - General Subjects
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 1619
- Issue
- 2
- Pages
- 177-186
- ISSN
- 0304-4165 (ISSN-L)
- OpenAlex
- W1999960925
- Cited by
- 47
- References
- 32
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 5 · 2018: 2 · 2017: 4 · 2016: 5 · 2014: 3 · 2012: 3
- FWCI
- 0.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Biochimica et Biophysica Acta (BBA) - General Subjects (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cooley's Anemia Foundation
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Physical Sciences › Chemistry › Inorganic Chemistry › Inorganic and Organometallic Chemistry
- Keywords
- pyridoxal isonicotinoyl hydrazone, hydrolysis, iron chelators, secondary iron overload, iron mobilization, iron(III) chelation, serum stability
- MeSH terms
- Animals, Cations, Cell Survival, Cells, Cultured, Half-Life, Hydrogen-Ion Concentration, Hydrolysis, Iron, Iron Chelating Agents, Isoniazid, Pyridoxal, Reticulocytes, Time Factors, Drug Design, Molecular Structure, Inhibitory Concentration 50, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hydrolysis of pyridoxal isonicotinoyl hydrazone and its analogs. https://app.cochat.ai/papers/10.1016/s0304-4165(02)00478-6
- The paper
- Buss, J. L., & Ponka, P. (2003). Hydrolysis of pyridoxal isonicotinoyl hydrazone and its analogs. Biochimica et Biophysica Acta (BBA) - General Subjects. https://doi.org/10.1016/s0304-4165(02)00478-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.